31, 1997, With The Dividends Reinvested Would Now Be Worth $85,572.14.

marijuana stocks with dividends On top of the skyrocketing stock price, the dividend payout has increased for 13 years straight. And the profits from the second marijuana stock with dividends we are about to show you are even more staggering. A $10,000 investment in this stock on Dec. 31, 1997, Medical marijuana with the dividends reinvested would now be worth $85,572.14. In comparison, the shares would only be worth $70,585.55 if the dividends weren’t reinvested. That means reinvesting dividends would’ve boosted your return by 21%. This stock has climbed 451% since it traded for $15.13 per share on Dec. 31, 1997. On top of that, this company has increased its dividend payout for the last seven years.

To read more visit https://moneymorning.com/2017/06/13/two-marijuana-stocks-with-dividends-to-own-right-now/

The Law Will Make It Legal For Anyone In The Country Over 18 Years Old To Possess Small Amounts Of Marijuana.

So how do you think the markets will react when legalization goes nationwide? We’re about to get a sneak preview, thanks to some pending legislation. The law will make it legal for Medical marijuana stocks anyone in the country over 18 years old to possess small amounts of marijuana. It will also give companies permission to market and sell marijuana products. Politicians seem in favor of passing the law… and it could go into effect as early as July 1, 2018. The twist is that it’s not American companies that will profit… and I’m not talking about proposed legislation in the United States. Instead, this legislation is happening in Canada. The companies that are poised to benefit the most are in the Great White North. As you may know, marijuana was criminalized across the United States in October 1937.

To read more visit https://dailyreckoning.com/path-riches-leads-north/

This Is Particularly True For Biotechs Developing Cannabinoid Drugs.

The share price of Aurora Cannabis (NASDAQOTH: ACBFF), for example, quadrupled in 2016 thanks in part to increased acceptance of medical marijuana in Canada. Aurora began selling medical marijuana in Jan. 2016 and had registered 10,800 active patients by late November. Aurora’s success, though, didn’t come about just because Canadians were more accepting of medical marijuana. The company took the right steps to reach out to patients and expanded its infrastructure quickly to keep up with demand. Others weren’t so smart and didn’t perform as well as Aurora did. Some marijuana stocks have achieved success for reasons other than increased public acceptance of marijuana. This is particularly true for biotechs developing cannabinoid drugs. For instance,GW Pharmaceuticals’ (NASDAQ: GWPH) stock soared in 2016 based on its pipeline success.

To read more visit Medical marijuana href=’http://www.foxbusiness.com/markets/2017/01/01/3-myths-about-marijuana-stocks.html’ rel=’nofollow’>http://www.foxbusiness.com/markets/2017/01/01/3-myths-about-marijuana-stocks.html

But Despite These Antics The Industry Has Been Too Attractive To Resist For Some Investors.

Suddenly everyone wants a slice of an industry that is already worth billions. The reaction to Shoenmakers’ appointment is thanks to the Australian/Dutch dual national’s legendary cannabis breeding reputation – fans lauded him as “The King of Cannabis” and the United States try to extradite him from Australia in the early 1990s. Arrested in Perth, he posted bail and then disappeared . The founder of Australia’s first listed medical cannabis company, Ross Smith, is only a few shades less colourful. He floated Phytotech (now MMJ Phytotech) on the ASX in January 2015 to a roaring response – climbing from 20?? on issue to 92?? on their second day – only to resign marijuana as executive director two weeks later over a threatening social media rant. Smith said his Facebook account had been hacked. But despite these antics the industry has been too attractive to resist for some investors. To give a sense of scale consider that medical marijuana sales hit $US4.9 billion ($6.5 billion) in the United States last year and will reach $US7.3 billion in 2020, according to research by marijuana investment group Archview.

To read more visit http://www.thecourier.com.au/story/4636580/how-high-is-too-high-for-australias-cannabis-stocks/?cs=9

Cara Is Angling Its Two Experimental Products In Development, Cr845 And Cr701, At Either Acute Or Chronic Pain, Or Pruritus, Which Is A Really Just Fancy Word For Severe Itching.

Better Know a Marijuana Stock: Cara Therapeutics With Marijuana Stocks this in mind, we’re going to take the time to analyze one marijuana stock each week until we’ve dissected all of the major players (i.e., those sporting a $200 million market cap, or larger). Here are the companies we’ve discussed so far; Today, we’re going to take a closer look at Cara Therapeutics (NASDAQ: CARA). Cara Therapeutics is a drug developer that shares a key similarity with Insys Therapeutics: its drug development pipeline isn’t entirely devoted to cannabinoid or endocannabinoid-mimetic drugs. In fact, Cara Therapeutics, which is entirely clinical-stage at this point, is almost exclusively focused on developing CR845, a kappa opioid receptor agonist (KORA) that has nothing to do with cannabis. We’ll get into Cara’s more direct cannabis ties in a moment. Cara is angling its two experimental products in development, CR845 and CR701, at either acute or chronic pain, or pruritus, which is a really just fancy word for severe itching. For the time being, Cara’s future lies with the development of its KORA-based drug, CR845, which is being dosed in IV and oral form in various ongoing studies. KORAs generally have a poor ability to transcend the blood-brain barrier, unlike opioid therapies, meaning they’re an ideal candidate to treat pain (and pruritus) without the traditional central nervous system side effects seen with opioids that can include nausea, sedation, depression, and addiction. CR845 is being advanced in four clinical studies: two IV formulations that include post-operative pain and pruritis associated with chronic kidney disease (CKD) and two oral formulations for chronic pain and general pruritus. In late March, Cara reported promising results from Part A of its phase 2/3 study of IV CR845 in CKD-associated pruritus, with the experimental therapy meeting both its primary and secondary endpoints.

To read more visit http://host.madison.com/business/investment/markets-and-stocks/better-know-a-marijuana-stock-cara-therapeutics/article_ca2b7c2f-9d85-55b8-995c-21cf4942378d.html

“it’s Quite A Journey We Have All Been On Since The Medical Cannabis Regulation And Safety Act Was Passed In 2015,” Ajax Said.

64, which legalized adult-use cannabis in the state. Regulations for production and sale of adult-use cannabis are expected by January 2018. “It’s quite a journey we have all been on since the Medical Cannabis Regulation and Safety Act was passed in 2015,” Ajax said. “I didn’t realize what I was getting into. I didn’t realize how much different cannabis is from alcohol. Alcohol is simple to understand. Cannabis is a lot more complicated. I had to start over to learn how best to regulate this industry.” The first panel was on how to invest in the cannabis industry. Speakers included Green Rush Emily and Morgan Paxhia, co-founders of Poseidon Asset Management, a San Francisco-based investment fund dedicated to funding cannabis-related enterprise.

To read more visit http://www.northbaybusinessjournal.com/northbay/sonomacounty/6975592-181/north-coast-cannabis-industry-conference

Put Simply, This Drug Definitely Has Megablockbuster Sales Potential, Especially With The Backing Of A Seasoned Biotech Like Gilead.

The crux of the situation is that Gilead and Galapagos are developing a JAK-1 selective inhibitor called filgotinib for a Green Rush range of high-value anti-inflammatory conditions, and this drug has rapidly emerged as a key clinical asset in Gilead’s quest to return to growth.  Getting to the point, Gilead’s CEO John Milligan noted on the call that the company is considering whether to accelerate filgotinib’s development in the wake of the FDA rejecting Incyte’s once-daily rheumatoid arthritis pill, baricitinib, earlier this year. What an accelerated development timeline means exactly isn’t altogether clear, but the drug is already in late-stage trials for rheumatoid arthritis, ulcerative colitis, and Crohn’s disease. Taken together, these three disease markets are currently worth around $28 billion in annual sales, and Galapagos is also planning additional proof-of-concepts studies for filgotinib for other anti-inflammatory conditions. Put simply, this drug definitely has megablockbuster sales potential, especially with the backing of a seasoned biotech like Gilead.   In all, Gilead appears primed to put the full weight of its clinical expertise to work to bring filgotinib to market as soon as possible. And that should mean that good things are in store for its partner Galapagos.  This biotech stock could have investors seeing “green” Sean Williams (Insys Therapeutics): If you’re an investor that has a long-term time horizon and a stomach for above-average risk, then Insys Therapeutics is the biotech stock you’ll want to consider adding to your portfolio this May. Insys, which is often lumped in as a marijuana stock for reasons we’ll get to in a moment, has seen its share price cut by three-quarters over the past two years. This pessimism stems from allegations and lawsuits surrounding its leading portfolio product Subsys, which is a sublingual breakthrough cancer pain medication. Allegations suggest that Subsys was being used off-label for about 80% of scripts written, and that Insys didn’t market the drug solely for its approved indications.

To read more visit https://www.fool.com/investing/2017/05/11/3-top-biotech-stocks-for-may.aspx

Jay Czarkowski, Founding Partner Of Cannabis Consultancy Canna Advisors, Offered Four Tips When Applying For A Cannabis License: Surround Yourself With Good People.

“So please help us get through this and insist people rename their strains.” For a more in-depth report on the “State of the Cannabis Market” keynote panel, visit bit.ly/cannabiskeynote . Jay Czarkowski, founding partner of cannabis consultancy Canna Advisors, offered four tips when applying for a cannabis license: Surround yourself with good people. (This suggestion came up many times during the conference and should be a standard operating procedure.) The team you put together and their relevant backgrounds are essential to a successful application. Make sure your business and financial plans are in order. Convey how your business benefits the community, especially patients, if applying for a medical license. Remember to answer every question on the application. This may sound obvious, but it is a common mistake applicants make. Carlos Campos, founder and CEO of C&H Auxiliary Safety Management, Inc., and Luke Tipton, a safety consultant from Milestone Safety Group, led the session entitled “OSHA Compliance: Why and Marijuana Stocks How to Prepare Now.” Speakers Carlos Campos (left) of C&H Auxiliary Safety Management and Luke Tipton of Milestone Safety Group spoke on preparing for “OSHA Compliance.” While safety regulations may seem overwhelming or even a bother, Tipton reminded attendees that the Occupational Safety and Health Administration (OSHA) expects all employers to be compliant. “It’s the employer’s responsibility,” he said. Campos added, “You should not fear reaching out to your local OSHA organization.” An OSHA consultant’s mission is to help employers with compliance.

To read more visit http://www.cannabisbusinesstimes.com/article/7-key-takeaways-from-cannabis-2017/

Why Isn’t Leaf?

Problem #1: This offering by a leading group of underwriters is not a “bought deal.” It is a “best efforts” financing. The preliminary prospectus says, “The obligations of the Underwriters under the Underwriting Agreement are conditional and may be terminated at their discretion on the basis of… “market out.”” In other words if the underwriters can’t sell it, they can exercise the “market out” clause and not complete the offering. This has to be puzzling at a time when much smaller, less prominent Canadian Licensed Producers have been rated worthy of “bought deal” status. Bought deals are reserved for the very best underwriting candidates of which LEAF would appear to be one. Why isn’t LEAF? Fact #2: The planned pricing of the offering is $9.50 to $10.50 per share. Problem #2: The preliminary prospectus discloses that on October 31, 2016 and November 3, 2016, LEAF sold shares at $2.96 per share. Between May 18, 2016 and as recently as February 2, 2017, LEAF issued shares at $.0001 per share. This means the current proposed pricing is over three times the price at which LEAF sold shares just over six months ago. At the same time, the Let’s Toke Green Rush Business Licensed Producer Index and the Let’s Toke Business Marijuana Composite Index are both down in the range of 5-10%. It isn’t evident in the documentation what happened in the last six months to make LEAF shares increase 300% in value against the general trend in the market.

To read more visit https://seekingalpha.com/article/4077574-medreleaf-ipo-disaster-waiting-happen

Frankly And This Site Make No Warranties Or Representations In Connection Therewith.

Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE MarketNewsUpdates.com MarketNewsUpdates.com News Commentary PALM BEACH, Florida, April 26, 2017 /PRNewswire/ — Through various introductions of latest innovative services, mergers and acquisitions along with product development, the CBD niche of the explosive cannabis industry continues to see impressive growth. Companies with recent developments of note in the legal marijuana industries include:PotNetwork Holding Inc. (OTC: POTN), Marijuana Stocks Medical Marijuana, Inc. (OTC: MJNA), Amfil Technologies, Inc. (OTC: AMFE), Players Network (OTC: PNTV), MassRoots, Inc. (OTC: MSRT) PotNetwork Holding Inc.(OTC Pink: POTN) reported today that after starting 2017 with the advantageous acquisition of Diamond CBD, Inc. and the transition back into the cannabis, hemp and related markets, the company has surpassed initial quarterly projections of 1.7 million in gross revenues. Management is pleased to announce that realized first quarter figures had exceeded expectation by over $100,000, for a total of $1,858,347.48. Having, at the beginning of the year, set corporate sights on achieving the goal of $1.7 million for the quarter, management had put in motion an aggressive effort to build a strong and thriving sales pipeline for 2017.

To read more visit http://www.wsfa.com/story/35251907/revenues-in-lucrative-legal-marijuana-and-cbd-oil-markets-continue-to-climb-in-hand-with-consumer-demand